Is Bristol-Myers Squibb a growth company?
Bristol-Myers Squibb (NYSE: BMY) is a large-cap, long-established pharmaceutical company that has been struggling to show revenue growth. I believe it is in a good position to become a growth company again, though there are risks to that scenario. This article will analyze Q2 2022 results with an eye to what they say about future growth.
Is Bristol-Myers Squibb the Big 8 Momentum Stock to watch?
When I last covered Bristol-Myers Squibb for Seeking Alpha back in mid March I suggested that the company may be the momentum stock to watch in the "Big 8" US Pharmaceutical sector.
Is Bristol Myers Squibb a safe haven for investors?
Bristol Myers Squibb is growing rapidly and can serve as a safe haven for investors worried about the current state of the market and economy. The company faces some risks with patent expirations and high debt, but its promising pipeline and increasing free cash flow will help mitigate both of these issues.
When will the correction end for Bristol-Myers Squibb's EBITDA?
Bristol-Myers Squibb: When Will The Correction End? Bristol-Myers Squibb's EBITDA margin is 47.2% at the end of Q1 2022, which is one of the largest values in the pharmaceutical industry. Due to the loss of exclusivity, Revlimid's sales were $2,797 million in Q1 2022, down 16% from Q1 2021.
See more
How much is Bristol Myers stock?
$74.70$ 74.75CloseChgChg %$74.70-0.11-0.15%
What is the ex dividend date for Bristol Myers Squibb?
BMY's annual dividend yield is 2.75%. When is Bristol Myers ex-dividend date? Bristol Myers's upcoming ex-dividend date is on Jun 29, 2022. Bristol Myers shareholders who own BMY stock before this date will receive Bristol Myers's next dividend payment of $0.54 per share on Jul 31, 2022.
Does BMY have moat?
Morningstar has rated BMY as a company with a wide economic moat. Its gross margin of 79% is higher than that of ABBV (69%).
Is Bristol Myers Squibb a dividend stock?
Category: NEW YORK--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of fifty-four cents ($0.54) per share on the $. 10 par value common stock of the company.
Is Bristol Myers a buy or sell?
For example, a stock trading at $35 with earnings of $3 would have an earnings yield of 0.0857 or 8.57%. A yield of 8.57% also means 8.57 cents of earnings for $1 of investment....Momentum Scorecard. More Info.Zacks RankDefinitionAnnualized Return1Strong Buy24.75%2Buy18.15%3Hold9.70%4Sell5.35%2 more rows
Is BMY a good long term investment?
Bristol-Myers has multiple top-selling drugs in its portfolio that generate billions in revenue. The company is a money-making machine that could bring in $50 billion in free cash over the next few years. Its low valuation and high dividend yield make it an all-around safe stock to just buy and hold.
Is Bristol Myers Squibb a buy sell or hold?
Bristol-Myers Squibb has received a consensus rating of Hold. The company's average rating score is 2.45, and is based on 6 buy ratings, 4 hold ratings, and 1 sell rating.
What is Mo dividend payout ratio?
2.92% Dividend Yield to Dividend Payout Ratio (TTM) 10.57%
Does Warren Buffett own BMY stock?
Bristol-Myers Squibb Warren Buffett reversed course on Bristol Myers Squibb (BMY, $59.62) in a big way in the fourth quarter, cutting his company's stake by 76%. Berkshire Hathaway has now sold shares in BMY during every quarter of 2021.
Does Warren Buffett own BMY?
Buffett sold off the holding company's remaining stake in Bristol-Myers Squibb (BMY, $76.91), dumping 5.2 million shares. The move was largely telegraphed three months ago when Berkshire cut its BMY stake by 76% during the fourth quarter of 2021.
Why is Bristol Myers stock cheap?
The drug mix up 28 percent of revenue in the first half of 2021, the first half of Bristol Myers Squibb's overall revenue, so that's a big chunk that it's going to lose and that explains why Bristol Myers Squibb looks so cheap right now.
Why is BMY stock dropping?
Bristol Myers Stock Drops After 'Fairly Uninspiring' Earnings Beat. The company effectively lowered its sales guidance for 2022 slightly, saying it now expects $46 billion in sales for the year.